Content about Neglected diseases

March 20, 2014

The Food and Drug Administration announced the approval of Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Leishmaniasis is caused by Leishmania, a parasite transmitted to humans through sand fly bites.

SILVER SPRING, Md. — The Food and Drug Administration announced the approval of Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Leishmaniasis is caused by Leishmania, a parasite transmitted to humans through sand fly bites. It's the first FDA-approved drug to treat cutaneous or mucosal leishmaniasis.

July 18, 2013

Almost twice as many drugs for neglected diseases have received regulatory approval around the world over the past few years compared with the beginning of the last decade, according to a new study.

BOSTON — Almost twice as many drugs for neglected diseases have received regulatory approval around the world over the past few years compared with the beginning of the last decade, according to a new study.

June 27, 2012

A bill passed in the Senate will provide measures to speed up the development of treatments for people who desperately need them.

WASHINGTON — A bill passed in the Senate will provide measures to speed up the development of treatments for people who desperately need them.

The Senate voted Tuesday to pass S. 3187, the Food and Drug Administration Safety and Innovation Act, which now awaits President Barack Obama's signature. The House approved a similar bill last week.

November 21, 2011

A subsidiary of Aceto Corp. has launched two generic drugs for treating infectious diseases, the company said Monday.

PORT WASHINGTON, N.Y. — A subsidiary of Aceto Corp. has launched two generic drugs for treating infectious diseases, the company said Monday.

Aceto said its Rising Pharmaceuticals subsidiary launched flucytosine capsules, a version of Valeant Pharmaceuticals International's Ancobon, used to treat serious infections; and chloroquine phosphate tablets, a generic version of Sanofi's malaria drug Aralen. The drugs' branded versions had sales of $20 million during the 12-month period ended in June, Aceto said.

November 3, 2010

A vaccine for the mosquito-borne illness dengue fever is in the final stages of development,...

LYON, France A vaccine for the mosquito-borne illness dengue fever is in the final stages of development, Sanofi-Aventis said Thursday.

 

Sanofi said the first phase-3 trial of the vaccine was under way in Australia.